Cerenome, Inc. CNSY
0.95 USD +0.18 (+23.32%)
Regular-session close
0.91 -0.04 -3.81%
After hours · Nov 13, 7:54 PM ET
0.813 Day range 1.18
0.57 52-week range 18.00
- YTD
- -92.55%
- 1 year
- -92.69%
- Market cap
- 7.21M
- EPS (ttm)
- -3.36
- YTD return
- -92.55%
- 1-year return
- -92.69%
- Volume
- 8.13M
- Avg volume
- 767.13K
- Open
- 0.813
- Previous close
- 0.7705
- Day's range
- 0.813 – 1.18
- 52-week range
- 0.57 – 18.00
5D +0.2877 (+43.43%)
Financials — quick view
CNSY Revenue — quarterly 411.00K
CNSY Net income — quarterly -9.01M
CNSY EPS — quarterly -1.31
News
Cerenome (CNSY) Reports Q3 Loss, Beats Revenue Estimates 
Cerenome Q3 EPS $(1.14) Misses $(0.95) Estimate, Sales $722.000K Miss $920.333K Estimate 
Cerenome Reports Third Quarter 2026 Financial Results and Business Highlights Featuring REYOBIQ ReSPECT- LM Data and CNSide Commercial and Reimbursement Progress 
12 Health Care Stocks Moving In Friday's Intraday Session 
Cerenome to Review REYOBIQ ReSPECT-LM Data Presented at SNO Conference and Provide CNSide Commercial Update on November 16 
Cerenome Appoints Director Ron Andrews as Chief Business Officer 
12 Health Care Stocks Moving In Wednesday's Intraday Session 
CNSide Diagnostics Inks National In-Network Laboratory Ancillary Provider With Aetna Health Plans - 12 Health Care Stocks Moving In Tuesday's Intraday Session
Cerenome To Report Poster Presentation Of Interim Data From Its Current ReSPECT-LMM Multidose Trial Of REYOBIQ At 31st Annual Meeting And Education Day
Your note
Sign in to keep a note on CNSY — it syncs with the Stock Master app.